Objective To investigate the impact of liraglutide on contrast-induced nephropathy(CIN)and prognosis in elderly patients with type 2 diabetes(T2DM)after PCI.Methods A ret-rospective trial was conducted on 364 elderly T2DM patients undergoing PCI in Department of Cardiology of Tianjin Chest Hospital from January 2021 to June 2022.According to whether lira-glutide was used in the past,they were divided into liraglutide group(n=145)and control group(n=219).Their general clinical data were collected in the two groups.Propensity score matching was used to adjust confounding factors and to assign the patients.After propensity score matc-hing,there were 220 patients finally included,with 110 in each group.The levels of serum creati-nine(Scr),blood urea nitrogen(BUN),neutrophil gelatinase-associated lipocalin(NGAL),hyper-sensitive C-reactive protein(hs-CRP),malondialdehyde(MDA),superoxide dismutase(SOD),Bax/BCL-2 and Caspase 9,and incidence of CIN were compared before and in 48 h after PCI be-tween the matched patients from the two groups.These patients were followed up for 18 months after discharge.Multivariate logistic regression analysis was employed to determine the effect of liraglutide on the occurrence of CIN.Kaplan-Meier curve analysis and Log rank test were applied to compare the differences in the incidence of major adverse cardiovascular events(MACE)be-tween 2 groups.Results The levels of Scr,BUN,NGAL,hs-CRP,and MDA were significantly lower,and SOD level was obviously higher in the liraglutide group than the control group in 48 h after PCI(P＜0.05,P＜0.01).The liraglutide group had notably lower incidence of CIN than the control group within 48 h after PCI(7.27％vs 16.36％,P＜0.05).Multivariate logistic regression analysis indicated liraglutide as an independent protective factor against CIN(OR=0.341,95％CI:0.128-0.906,P=0.031).During the median follow-up period of 14.75(12.60,16.33)months,a lower MACE occurrence rate was seen in the liraglutide group than the control group(log rank x2=5.656,P=0.017).Conclusion Liraglutide can reduce the incidences of CIN and MACE in elderly T2DM patients after PCI,which may be associated with its anti-inflammatory and antioxidant effects.

Objective To investigate the influences of Qishen Yiqi dropping pills on serum IL-18 level and prognosis in elderly hypertension patients complicated with acute coronary syndrome(ACS).Methods A prospective study was performed on 330 patients with hypertension compli-cated by ACS treated in our hospital from January 2020 to January 2022.They were randomly di-vided into dropping pills treatment group(n=164)and control group(n=166).The control group received standard Western medicine treatment,and on the basis of the treatment,the treat-ment group were given Qishen Yiqi dropping pills.The baseline clinical data,serum IL-18 level,blood pressure,and blood lipid and glucose levels in 1 year after treatment and the incidence rate of MACE within 1 year of follow-up were compared between the two groups.Multivariate logistic regression analysis was applied to identify influencing factors for reoccurrence of MACE in elderly patients with hypertension complicated by ACS.ROC curve was plotted to study the value of IL-18 in predicting MACE in the patients.Results In 1 year after treatment,SBP and DBP levels,serum levels of IL-18,LDL-C and TC,and the incidence of MACE were significantly lower in the treatment group than the control group(P＜0.05).Multivarate logistic regression analysis re-vealed that Qishen Yiqi dropping pill was an independent protective factor for MACE(OR=0.259,95％CI:0.087-0.772,P=0.010),while higher serum IL-18 level was a risk factor for MACE(OR=1.075,95％CI:1.046-1.106,P=0.000)in the elderly hypertension patients com-plicated by ACS.The AUC value of serum IL-18 level in predicting MACE in the patients with hypertension complicated by ACS was 0.786(95％CI:0.696-0.877,P＜0.01),with a sensitivity and a specificity of 65.00％and 90.00％respectively.Conclusion Serum IL-18 level has a predic-tive value for prognosis in elderly hypertension patients complicated with ACS.Qishen Yiqi drop-ping pills can reduce serum IL-18 level,blood pressure and lipids,attenuate inflammatory re-sponse,and consequently decrease the risk of MACE and improve prognosis in the patients.